Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Core Scientific (CORZ) over the last 5 years, with Q3 2025 value amounting to $453.4 million.

  • Core Scientific's Cash & Equivalents rose 7921.3% to $453.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $453.4 million, marking a year-over-year increase of 7921.3%. This contributed to the annual value of $836.2 million for FY2024, which is 155883.08% up from last year.
  • As of Q3 2025, Core Scientific's Cash & Equivalents stood at $453.4 million, which was up 7921.3% from $581.3 million recorded in Q2 2025.
  • Core Scientific's Cash & Equivalents' 5-year high stood at $836.2 million during Q4 2024, with a 5-year trough of $1.6 million in Q3 2021.
  • Moreover, its 5-year median value for Cash & Equivalents was $96.1 million (2024), whereas its average is $189.9 million.
  • Over the last 5 years, Core Scientific's Cash & Equivalents had its largest YoY gain of 618628.99% in 2022, and its largest YoY loss of 8652.43% in 2022.
  • Over the past 5 years, Core Scientific's Cash & Equivalents (Quarter) stood at $117.9 million in 2021, then tumbled by 86.52% to $15.9 million in 2022, then soared by 217.36% to $50.4 million in 2023, then soared by 1558.83% to $836.2 million in 2024, then tumbled by 45.77% to $453.4 million in 2025.
  • Its last three reported values are $453.4 million in Q3 2025, $581.3 million for Q2 2025, and $697.9 million during Q1 2025.